相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review
Oncology
Jerome Barriere et al.
Summary: Considering the high risk and decreased immunogenicity in cancer patients, booster dosing after a full two-dose vaccination appears necessary. This review provides evidence to assist oncologists in determining the timing of anti-SARS-Cov2 antibody dosage and proposing early third dose if needed.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Medicine, General & Internal
Avishay Spitzer et al.
Summary: A booster dose of BNT162b2 vaccine was associated with a significantly lower risk of SARS-CoV-2 infection among health care workers who were previously vaccinated with a 2-dose series of the same vaccine. The study was conducted in Israel and included 1928 participants with a median follow-up of 39 days.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Immunology
Oktavija Dakovic Rode et al.
Summary: Research on post-vaccination antibody dynamics is crucial in estimating COVID-19 vaccine efficacy. This study found that antibody levels significantly increased one month after vaccination and exponentially decreased three and six months after complete vaccination. Participants with a prior history of COVID-19 had higher antibody levels, particularly after the first dose. Six months after vaccination, antibody levels were comparable to those seen in COVID-19-naive participants after the first vaccine dose.
Letter
Virology
Ali Umit Keskin et al.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Multidisciplinary Sciences
Maria Elena Romero-Ibarguengoitia et al.
Summary: This study found that a third dose of the BNT162b2 vaccine administered six months after the original regimen increased the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers. The booster dose was well tolerated and caused fewer adverse events compared to the first two doses, although specific symptoms such as fatigue, myalgia, arthralgia, fever, and adenopathy were more common.
Article
Virology
Anita Siller et al.
Summary: A study conducted in Tyrol, Austria between June 2020 and September 2021 found that the seroprevalence of anti-SARS-CoV-2 antibodies increased from 3.4% to 82.7%, largely due to vaccination. Antibody levels gradually declined after vaccination or infection.
Article
Immunology
Jennifer Kertes et al.
Summary: Based on data from a large health maintenance organization in Israel, our analysis found that IgG levels decrease over time in fully vaccinated individuals, and there is an inverse relationship between IgG titer and subsequent PCR-confirmed infection. Early vaccinated individuals during the vaccination campaign were more likely to become infected, and those aged 60 and above had lower initial IgG levels and were at higher risk for infection.
EMERGING INFECTIOUS DISEASES
(2022)
Letter
Medicine, General & Internal
Diana Zhong et al.
Summary: This study compares the durability of antibodies in individuals who received mRNA SARS-CoV-2 vaccine with prior infection and those without infection.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Sara Y. Tartof et al.
Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.
Article
Medicine, General & Internal
Yair Goldberg et al.
Summary: The immunity against the delta variant of SARS-CoV-2 waned in all age groups in Israel a few months after receiving the second dose of the vaccine, leading to an increase in infection and severe cases.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Einav G. Levin et al.
Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Hiam Chemaitelly et al.
Summary: In a study conducted in Qatar involving over 900,000 participants, vaccine effectiveness peaked at 77.5% in the first month after the second dose. However, it declined afterwards to as low as 20% in months 5 through 7 after vaccination, while protection against severe Covid-19 remained above 90% for at least 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Infectious Diseases
Julien Favresse et al.
Summary: The CRO-VAX HCP study investigated the early antibody response in healthcare professionals who received two doses of the BNT162b2 mRNA COVID-19 vaccine. Results showed that in previously infected individuals, a single dose of the vaccine may be sufficient, as they had higher antibody titres compared to uninfected individuals.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Microbiology
Madhusudhanan Narasimhan et al.
Summary: This study evaluated antibody responses in different populations after vaccination using new serological assays, demonstrating a significant increase in IgGSP and IgMSP values post vaccination.
JOURNAL OF CLINICAL MICROBIOLOGY
(2021)
Article
Immunology
Jean-Louis Bayart et al.
Summary: Data from this study showed a significant decline in antibodies levels at day 180 post SARS-CoV-2 vaccination, with a more pronounced decrease in neutralizing antibodies. The estimated half-life of IgG was around 21 days in seronegative individuals and 53 days in seropositive individuals, while the half-life of total antibodies ranged from 68 to 114 days. The decline in neutralizing antibodies was particularly stark, with around 45% of subjects testing negative at day 180.
Article
Immunology
Chin-Shern Lau et al.
Summary: The study revealed that COVID-naive subjects from Southeast Asia showed sustained and elevated antibody responses post COVID-19 vaccination. Majority of the participants tested positive for antibodies 10 days after dose 1, with a small percentage showing neutralizing antibody positivity. Even at 180 days, some antibodies remained active, with neutralizing antibody titers expected to stay reactive up to 241 days post-vaccination.
Letter
Medicine, General & Internal
Nicole Doria-Rose et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Infectious Diseases
Tal Brosh-Nissimov et al.
Summary: A study in Israel showed that a minority of fully vaccinated individuals with significant comorbidities may still develop severe COVID-19, with a high mortality rate. Further research on this vulnerable population may help improve their protection.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Medicine, General & Internal
Moriah Bergwerk et al.
Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
S. J. Thomas et al.
Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Masaaki Takeuchi et al.
Summary: The severity of reactions after the second dose of the mRNA vaccine BNT162b2 may not accurately reflect antibody production levels. While spike IgG levels were correlated with age and levels after the first dose, adverse event scores were not significantly associated with log-transformed spike IgG levels after the second dose.
Article
Immunology
Kristen A. Earle et al.
Summary: The study found a strong correlation between antibody titers and efficacy when assessing different COVID-19 vaccines, supporting the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.
Article
Critical Care Medicine
Yaniv Lustig et al.
Summary: The study assessed early antibody responses after Pfizer-BioNTech BNT162b2 COVID-19 vaccine in Israeli healthcare workers. Results showed that 77% of participants had positive IgG response at week 3 after the first vaccine dose, with lower responses in older and immunosuppressed individuals. Timely second dose vaccinations are particularly important for these populations to enhance antibody responses and reduce breakthrough infections.
LANCET RESPIRATORY MEDICINE
(2021)
Article
Immunology
Giovanna Cocomazzi et al.
Summary: The study investigated the antibody durability in healthcare workers after mRNA COVID-19 vaccination, finding a potential inverse correlation between early response and antibody levels at 90 days post-vaccination.
Article
Health Care Sciences & Services
Paul Naaber et al.
Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.
LANCET REGIONAL HEALTH-EUROPE
(2021)
Article
Immunology
Julien Favresse et al.
Summary: The study aimed to assess the antibody response in healthcare professionals who had received the BNT162b2 mRNA COVID-19 vaccine, finding a decline in antibody levels at 3 months post-vaccination but maintaining a robust immune response.
EMERGING MICROBES & INFECTIONS
(2021)
Article
Multidisciplinary Sciences
Jin Li
Article
Statistics & Probability
L Lin et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION
(2002)
